Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

PCSK9 Expert Opinions Prof. Ulf Landmesser states that the results of both FOURIER and SPIRE fit into the concept that lowering LDL to very low levels results in a reduction in CV events

Video navigation menu

LDL-lowering with PCSK9 inhibition is safe 00:28
Observations of very low achieved LDL-c levels further confirm the concept that LDL-lowering is beneficial 01:05
The SPIRE studies highlight that similar agents need separate safety studies 02:07
Identification of patients in whom the largest absolute risk reduction can be achieved 02:48

Educational information

This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice

The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME

Disclosures

Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany

Funding

Funding was provided by an unrestricted educational grant from Amgen

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.